New Rhein is a global venture capital firm investing in healthcare.
Business Model: B2B
Revenue: $0
Employees: 0-0
Address: Two Logan Square 110 N. 18th St.,
City: Philadelphia
State: PA
Zip: 19103
Country: US
New Rhein is a venture capital firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience. New Rhein invests in businesses that utilize proven products in new applications (e.g., new indications, new dosage forms, 505(b2)). The company compiles syndicates of operationally focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in the development, regulatory, reimbursement, marketing, and/or contract manufacturing. New Rhein provides an understanding of what would be attractive to strategic partners and works backward to help its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics, and respiratory drug/device inhalers.
Contact Phone:
+12154197830
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2016 | Softhale | Series A | - |
8/2022 | Theranica | Series C | 0 |
10/2020 | Butterfly Medical | Series B | 0 |
12/2018 | Neuraptive Therapeutics | Series A | 11.5M |
9/2020 | American Injectables | Series A | 10M |
9/2017 | Neuraptive Therapeutics | Seed Round | 1M |
12/2012 | Biocartis | Series D | 0 |
5/2014 | Chase Pharmaceuticals | Series B | 21M |
8/2022 | Theranica | Series C | 0 |
10/2020 | Butterfly Medical | Series B | 0 |
9/2020 | American Injectables | Series A | 0 |
12/2018 | Neuraptive Therapeutics | Series A | 0 |
9/2017 | Neuraptive Therapeutics | Seed Round | 0 |
11/2016 | Softhale | Series A | - |
5/2014 | Chase Pharmaceuticals | Series B | 0 |
12/2012 | Biocartis | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|